Stoke Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Stoke Therapeutics
STOK Stock  USD 9.36  0.10  1.06%   
Stoke Therapeutics financial statements provide useful quarterly and yearly information to potential Stoke Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Stoke Therapeutics financial statements helps investors assess Stoke Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Stoke Therapeutics' valuation are summarized below:
Gross Profit
16.7 M
Market Capitalization
495.8 M
Enterprise Value Revenue
15.7777
Revenue
16.7 M
Earnings Share
(2.06)
There are currently one hundred twenty fundamental trend indicators for Stoke Therapeutics that can be evaluated and compared over time across competition. We recommend to double-check Stoke Therapeutics' current fundamental drivers against the all of the trends between 2010 and 2025. The value of Market Cap is estimated to slide to about 252.8 M. The Enterprise Value is projected to slide to about 45.9 M

Stoke Therapeutics Total Revenue

10.6 Million

Check Stoke Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Stoke Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 10.6 M, Interest Income of 131.1 K or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 30.42, Dividend Yield of 0.0 or PTB Ratio of 1.37. Stoke financial statements analysis is a perfect complement when working with Stoke Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Stoke Therapeutics Correlation against competitors.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.

Stoke Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets213.7 M262.6 M115.8 M
Slightly volatile
Other Current Liabilities8.7 M13.5 M6.4 M
Slightly volatile
Total Current Liabilities37.2 M35.4 M12.5 M
Slightly volatile
Other Liabilities44.8 M42.7 M10.4 M
Slightly volatile
Property Plant And Equipment Net15 M14.3 M4.6 M
Slightly volatile
Accounts Payable1.3 M1.9 M784.1 K
Slightly volatile
Cash167.7 M220.2 M91.7 M
Slightly volatile
Non Current Assets Total15.7 M15 M4.9 M
Slightly volatile
Non Currrent Assets Other373.5 K654.4 K237.3 K
Slightly volatile
Other Assets621.6 K654.4 K15.8 M
Pretty Stable
Cash And Short Term Investments199.2 M231.6 M106.9 M
Slightly volatile
Common Stock Shares Outstanding32.6 M50.6 M23.8 M
Slightly volatile
Liabilities And Stockholders Equity213.7 M262.6 M115.8 M
Slightly volatile
Non Current Liabilities Total45.8 M43.7 M10.7 M
Slightly volatile
Capital Surpluse315.1 M555.6 M197.2 M
Slightly volatile
Other Current Assets16.8 M16 M5.1 M
Slightly volatile
Other Stockholder Equity358.4 M645.6 M210.6 M
Slightly volatile
Total Liabilities83 M79.1 M23.2 M
Slightly volatile
Property Plant And Equipment Gross23.1 M22 M6 M
Slightly volatile
Total Current Assets206.9 M247.6 M111.5 M
Slightly volatile
Non Current Liabilities Other5.9 M5.6 M1.5 M
Slightly volatile
Common Stock3.5 K5.8 K2.4 K
Slightly volatile
Property Plant Equipment4.1 M7.7 M2.8 M
Slightly volatile
Net Receivables69.9 K73.6 K186.2 K
Pretty Stable
Capital Stock4 K5.8 K3 K
Slightly volatile
Short and Long Term Debt Total1.7 M2.4 M677 K
Slightly volatile
Capital Lease Obligations1.9 M2.4 M1.4 M
Slightly volatile

Stoke Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3 M2.8 M829.1 K
Slightly volatile
Selling General Administrative23.8 M47.5 M14.8 M
Slightly volatile
Other Operating Expenses149.2 M142.1 M47.7 M
Slightly volatile
Research Development99.3 M94.6 M31.3 M
Slightly volatile
Total Operating Expenses149.2 M142.1 M47.7 M
Slightly volatile
Reconciled Depreciation3 M2.8 M826 K
Slightly volatile
Non Operating Income Net Other295.5 K150.3 K608.2 K
Slightly volatile
Selling And Marketing Expenses1.8 M2 M2.2 M
Slightly volatile

Stoke Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock909.7 K957.6 K26.9 M
Pretty Stable
Stock Based Compensation30.5 M29 M8.3 M
Slightly volatile
Begin Period Cash Flow138.1 M131.2 M72.3 M
Slightly volatile
Depreciation3 M2.8 M829.1 K
Slightly volatile
Other Non Cash Items2.3 M2.2 M663.6 K
Slightly volatile
Capital Expenditures1.7 M1.9 M925.8 K
Slightly volatile
Total Cash From Financing Activities54.9 M47.7 M39 M
Slightly volatile
End Period Cash Flow168 M220.8 M91.9 M
Slightly volatile
Change To Netincome27.6 M26.3 M7.8 M
Slightly volatile
Change To Liabilities58.2 M55.4 M13.8 M
Slightly volatile
Issuance Of Capital Stock67.4 M40.3 M96.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio30.4230.3128.9582
Very volatile
Days Sales Outstanding2.913.0614.5965
Slightly volatile
Stock Based Compensation To Revenue1.892.591.9567
Slightly volatile
Capex To Depreciation0.720.753.1286
Slightly volatile
EV To Sales5.235.5117.2025
Slightly volatile
Inventory Turnover0.260.290.3173
Slightly volatile
Days Of Inventory On Hand9031 K1.1 K
Slightly volatile
Payables Turnover4.364.151.6983
Slightly volatile
Sales General And Administrative To Revenue3.144.243.3048
Slightly volatile
Research And Ddevelopement To Revenue6.268.436.6016
Slightly volatile
Capex To Revenue0.280.210.3016
Slightly volatile
Cash Per Share4.814.123.2474
Slightly volatile
Days Payables Outstanding86.4190.96443
Slightly volatile
Income Quality0.860.890.8758
Slightly volatile
Current Ratio7.638.0410.7367
Slightly volatile
Receivables Turnover63.3112337.3892
Slightly volatile
Graham Number10.7412.547.7614
Slightly volatile
Capex Per Share0.03910.03310.0298
Slightly volatile
Revenue Per Share0.290.230.3041
Slightly volatile
Interest Debt Per Share0.10.05390.1419
Slightly volatile
Debt To Assets0.00990.01040.6179
Slightly volatile
Operating Cycle2.913.06932
Slightly volatile
Days Of Payables Outstanding86.4190.96443
Slightly volatile
Ebt Per Ebit1.061.050.9915
Very volatile
Total Debt To Capitalization0.01390.01470.8821
Slightly volatile
Quick Ratio7.638.0410.7149
Slightly volatile
Net Income Per E B T0.750.830.8877
Very volatile
Cash Ratio6.797.149.8876
Slightly volatile
Days Of Inventory Outstanding9031 K1.1 K
Slightly volatile
Days Of Sales Outstanding2.913.0614.5965
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.840.921.0158
Slightly volatile
Fixed Asset Turnover0.990.811.0386
Slightly volatile
Debt Ratio0.00990.01040.6179
Slightly volatile
Price Sales Ratio30.4230.3128.9582
Very volatile
Asset Turnover0.04770.04420.0475
Slightly volatile
Gross Profit Margin0.580.640.7019
Slightly volatile

Stoke Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap252.8 M266.1 M486.9 M
Pretty Stable
Enterprise Value45.9 M48.3 M394.8 M
Very volatile

Stoke Fundamental Market Drivers

Cash And Short Term Investments201.4 M

Stoke Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Stoke Therapeutics Financial Statements

Stoke Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Stoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue17.6 M11.5 M
Total Revenue10.1 M10.6 M
Cost Of Revenue5.4 M5.7 M
Stock Based Compensation To Revenue 2.59  1.89 
Sales General And Administrative To Revenue 4.24  3.14 
Research And Ddevelopement To Revenue 8.43  6.26 
Capex To Revenue 0.21  0.28 
Revenue Per Share 0.23  0.29 
Ebit Per Revenue(15.03)(15.78)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock:
How To Invest In Stoke
Details
Is Stoke Stock a good investment?
Details
What is Stoke Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Stoke Therapeutics Correlation against competitors.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.06)
Revenue Per Share
0.328
Quarterly Revenue Growth
0.479
Return On Assets
(0.28)
Return On Equity
(0.52)
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY